Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survivalEmma L. Barber, Joanne M. Garrett, Stacie B. Dusetzina et al.|Gynecologic Oncology|2017Cited by 20
Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in MedicareBrian D. Cortese, Ruchika Talwar, Stacie B. Dusetzina et al.|Journal of Clinical Oncology|2023Cited by 18
Out-of-pocket costs for commercially insured patients with localized prostate cancerChristopher J.D. Wallis, Daniel A. Barocas, Amy N. Luckenbaugh et al.|Urologic Oncology Seminars and Original Investigations|2021Cited by 10
Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In SituChelsea Anderson, Hazel B. Nichols, Aaron N. Winn et al.|Journal of Cancer Epidemiology|2017Cited by 9
Estimating the Impact of the Inflation Reduction Act on the Out-of-Pocket Costs for Medicare Beneficiaries With Advanced Prostate CancerBrian D. Cortese, Ruchika Talwar, Stacie B. Dusetzina et al.|Urology Practice|2023Cited by 9